Why it matters
AI adoption increasingly requires a post-deployment evidence and monitoring architecture, not only premarket validation.
Decision implication
Add real-world monitoring, drift detection, human-AI interaction, and response protocols to P4L's AI adoption/evidence standard.
Who or what is affected
- FDA
- AI medical-device developers
- hospitals
- clinicians
- quality teams
- patients
Evidence and sources
E5 — official FDA source
P4L distinguishes the sourced event from the interpretation above. Participation, funding, proposed policy, or program inclusion does not by itself establish clinical effectiveness.
What P4L is watching next
- New guidance
- postmarket requirements
- performance-monitoring standards
- drift methodologies.
Related proof records
- No linked public proof claim yet.